CERo Therapeutics
CERO

$0.0998

2.09%

Market Cap: $5.13M

About: CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 2

100% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 2 (+1) [Q2]

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

67% more funds holding

Funds holding: 9 [Q1] → 15 (+6) [Q2]

1.74% more ownership

Funds ownership: 11.17% [Q1] → 12.91% (+1.74%) [Q2]

88% less capital invested

Capital invested by funds: $4.82M [Q1] → $557K (-$4.26M) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for CERO.

See Analyst Rankings

Financial journalist opinion

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. `

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

Company anticipates near term filing of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announced it successfully executed pre-IND manufacturing activities for its lead therapeutic, CER-1236.

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

CERo Therapeutics, Inc. Provides Corporate Update for Shareholders

SOUTH SAN FRANCISCO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq:CERO) (“CERo”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, provides shareholders with a corporate update reviewing activities since its entering the public market.

CERo Therapeutics, Inc. Provides Corporate Update for Shareholders

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms today announced the publication in Clinical Cancer Research, a journal of the American Association for Cancer Research, a paper titled “Therapeutic Targeting of TIM-4-L With Engineered T Cells for Acute Myeloid Leukemia.” The paper details preclinical s.

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

See News Rankings